Trius Therapeutics (TSRX)
Trius Therapeutics Revenue Growth: 262.1%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
TSRX Revenue Growth Rankings
| Overall | 98th percentile | 50 of 4363 |
| Sector | 95th percentile | 20 of 457 in Healthcare |
| Industry | 96th percentile | 1 of 25 in Medical Laboratories & Research |
TSRX Revenue Growth Range, Past 5 Years
| Minimum | 14.72% | Sep 2010 |
| Maximum | 1469% | Sep 2011 |
| Average | 290.9% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these TSRX related companies
TSRX News
$TSRX filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3KJ0
about 50 days ago by MarketBrief
about 50 days ago by MarketBrief
Piper Jaffray Sees Increased Chance of Trius (TSRX) Partnering in Europe Following Tedizolid Data
Apr 09, 2:49PM Street Insider
Apr 09, 2:49PM Street Insider
Trius Therapeutics (TSRX) Reports Encouraging Data for TR701-112 in Cellulitis Patients
Apr 02, 7:10AM Street Insider
Apr 02, 7:10AM Street Insider
Trius' Antibiotic Tedizolid Demonstrates High Efficacy in Patients With Cellulitis
Apr 02, 7:00AM GlobeNewswire
Apr 02, 7:00AM GlobeNewswire
$TSRX http://stks.co/36wB undervalued (IMHO) bioname, double bottomed just below 5$, can go higher now - $TSRX
about 65 days ago by LTbioinvestor
about 65 days ago by LTbioinvestor
Trius Therapeutics (TSRX) Posts Narrower than Expected Q4 Loss of 44c/Share
Mar 13, 8:12AM Street Insider
Mar 13, 8:12AM Street Insider
Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
Mar 13, 8:00AM GlobeNewswire
Mar 13, 8:00AM GlobeNewswire
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.60 from 2/17/2011.
about 85 days ago by TradeIdeasQuant
about 85 days ago by TradeIdeasQuant
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.90 from 2/18/2011.
about 87 days ago by TradeIdeasQuant
about 87 days ago by TradeIdeasQuant
$TSRX http://stks.co/2ds5 Biotech name. Bullish engulfing. Falling wedge.
about 91 days ago by VexTrades
about 91 days ago by VexTrades
$TSRX New 52 Week Low - Crossed daily lows support. Next support 4.90 from 2/18/2011.
about 92 days ago by TradeIdeasQuant
about 92 days ago by TradeIdeasQuant
I think $TSRX is worth accumulating in here. I also continue to add $CJES
about 122 days ago by britepathos
about 122 days ago by britepathos
Trius Therapeutics (TSRX) Underwriters Exercise Full Overallotment in Recent Offering
Jan 30, 7:05AM Street Insider
Jan 30, 7:05AM Street Insider
Baird Said Trius Therapeutics (TSRX) Equity Offering News Provides Attractive Entry Point
Jan 26, 9:58AM Street Insider
Jan 26, 9:58AM Street Insider
Trius Therapeutics (TSRX) Prices 8.6 Million Share Offering at $5.25/Share
Jan 26, 9:06AM Street Insider
Jan 26, 9:06AM Street Insider
$TSRX Announces Proposed Public Offering of Common Stock; Size Not Given
about 128 days ago by Benzinga
about 128 days ago by Benzinga
Buying Opportunity In Trius Therapeutics http://stks.co/22tw // $TSRX
about 130 days ago by JNapodano
about 130 days ago by JNapodano
Updated report on $TSRX: http://stks.co/1QHF // R&D Day Highlights Why Tedizolid Could Be "Best-In-Class" for #MRSA.
about 177 days ago by JNapodano
about 177 days ago by JNapodano
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TSRX | 5.13 | +0.12 | +2.40% | 193.19M |
| TSRI | 4.24 | +0.00 | +0.00% | 8.438M |
| TSRA | 13.59 | -0.10 | -0.73% | 709.83M |
| TSPT | 7.08 | -0.02 | -0.28% | 98.69M |
| TSON | 2.93 | -0.05 | -1.68% | 81.20M |
| TSO | 22.12 | -1.09 | -4.70% | 3.265B |
| TSM | 13.73 | -0.20 | -1.44% | 72.20B |
| TNB | 71.99 | +0.00 | +0.00% | 3.758B |
| TNAV | 6.01 | +0.20 | +3.44% | 241.81M |
| TNA | 47.26 | -0.31 | -0.65% |
